Last reviewed · How we verify

Biological Vaccine VLA1553

Valneva Austria GmbH · Phase 3 active Biologic

Biological Vaccine VLA1553 is a Inactivated viral vaccine Biologic drug developed by Valneva Austria GmbH. It is currently in Phase 3 development for Prevention of chikungunya virus infection in at-risk populations and travelers.

VLA1553 is an inactivated chikungunya virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against chikungunya virus infection.

VLA1553 is an inactivated chikungunya virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against chikungunya virus infection. Used for Prevention of chikungunya virus infection in at-risk populations and travelers.

At a glance

Generic nameBiological Vaccine VLA1553
SponsorValneva Austria GmbH
Drug classInactivated viral vaccine
TargetChikungunya virus structural and non-structural antigens
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The vaccine contains inactivated whole chikungunya virus particles that trigger both humoral (antibody) and cell-mediated immune responses. By exposing the immune system to non-infectious viral antigen, it primes protective immunity without causing active infection, reducing the risk of symptomatic chikungunya disease upon natural exposure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Biological Vaccine VLA1553

What is Biological Vaccine VLA1553?

Biological Vaccine VLA1553 is a Inactivated viral vaccine drug developed by Valneva Austria GmbH, indicated for Prevention of chikungunya virus infection in at-risk populations and travelers.

How does Biological Vaccine VLA1553 work?

VLA1553 is an inactivated chikungunya virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against chikungunya virus infection.

What is Biological Vaccine VLA1553 used for?

Biological Vaccine VLA1553 is indicated for Prevention of chikungunya virus infection in at-risk populations and travelers.

Who makes Biological Vaccine VLA1553?

Biological Vaccine VLA1553 is developed by Valneva Austria GmbH (see full Valneva Austria GmbH pipeline at /company/valneva-austria-gmbh).

What drug class is Biological Vaccine VLA1553 in?

Biological Vaccine VLA1553 belongs to the Inactivated viral vaccine class. See all Inactivated viral vaccine drugs at /class/inactivated-viral-vaccine.

What development phase is Biological Vaccine VLA1553 in?

Biological Vaccine VLA1553 is in Phase 3.

What are the side effects of Biological Vaccine VLA1553?

Common side effects of Biological Vaccine VLA1553 include Injection site pain or erythema, Myalgia, Headache, Fatigue.

What does Biological Vaccine VLA1553 target?

Biological Vaccine VLA1553 targets Chikungunya virus structural and non-structural antigens and is a Inactivated viral vaccine.

Related